Silo Pharma to Showcase Nose-to-Brain PTSD Treatment at 2026 Nasal Innovation Forum
Event summary
- Silo Pharma will present its patented nose-to-brain drug delivery technology for PTSD at the 2026 Nasal Innovation Forum on September 16-17.
- Preclinical data shows SPC-15 formulation and device met stability and performance specifications over nine months.
- Silo Pharma is a developmental-stage biopharmaceutical company focused on underserved conditions like PTSD and chronic pain.
- The company also operates QwikAgents, an AI subsidiary for research and workflow automation.
The big picture
Silo Pharma’s participation in the Nasal Innovation Forum underscores the growing importance of nasal drug delivery systems in treating CNS disorders. The company’s dual focus on biopharmaceutical innovation and AI-driven research reflects broader industry trends toward technology integration in drug development. Success in this space could position Silo Pharma as a key player in the evolving landscape of targeted psychiatric treatments.
What we're watching
- Regulatory Alignment
- How preclinical stability data will influence regulatory approval timelines for SPC-15.
- Market Differentiation
- Whether Silo Pharma’s nose-to-brain delivery technology can establish a competitive edge in PTSD treatment.
- AI Integration
- The pace at which QwikAgents’ AI platform will enhance Silo Pharma’s research and development capabilities.